MX2023004429A - Composiciones y metodos para tratar trastornos sanguineos. - Google Patents
Composiciones y metodos para tratar trastornos sanguineos.Info
- Publication number
- MX2023004429A MX2023004429A MX2023004429A MX2023004429A MX2023004429A MX 2023004429 A MX2023004429 A MX 2023004429A MX 2023004429 A MX2023004429 A MX 2023004429A MX 2023004429 A MX2023004429 A MX 2023004429A MX 2023004429 A MX2023004429 A MX 2023004429A
- Authority
- MX
- Mexico
- Prior art keywords
- hemolytic anemia
- thrombocytopenia
- antibody
- cold
- warm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093029P | 2020-10-16 | 2020-10-16 | |
| PCT/US2021/055216 WO2022081997A1 (en) | 2020-10-16 | 2021-10-15 | Compositions and methods for treating blood disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004429A true MX2023004429A (es) | 2023-07-11 |
Family
ID=81208704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004429A MX2023004429A (es) | 2020-10-16 | 2021-10-15 | Composiciones y metodos para tratar trastornos sanguineos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230391858A1 (enExample) |
| EP (1) | EP4228696A4 (enExample) |
| JP (1) | JP2023545501A (enExample) |
| KR (1) | KR20230087572A (enExample) |
| AU (1) | AU2021361067A1 (enExample) |
| CA (1) | CA3195798A1 (enExample) |
| MX (1) | MX2023004429A (enExample) |
| WO (1) | WO2022081997A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| KR20220083737A (ko) * | 2019-10-17 | 2022-06-20 | 애넥슨, 인코포레이티드 | 혈액 장애를 치료하기 위한 조성물 및 방법 |
-
2021
- 2021-10-15 AU AU2021361067A patent/AU2021361067A1/en active Pending
- 2021-10-15 US US18/032,084 patent/US20230391858A1/en active Pending
- 2021-10-15 WO PCT/US2021/055216 patent/WO2022081997A1/en not_active Ceased
- 2021-10-15 JP JP2023522978A patent/JP2023545501A/ja active Pending
- 2021-10-15 CA CA3195798A patent/CA3195798A1/en active Pending
- 2021-10-15 EP EP21881186.7A patent/EP4228696A4/en active Pending
- 2021-10-15 KR KR1020237016264A patent/KR20230087572A/ko active Pending
- 2021-10-15 MX MX2023004429A patent/MX2023004429A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021361067A9 (en) | 2024-07-11 |
| CA3195798A1 (en) | 2022-04-21 |
| EP4228696A1 (en) | 2023-08-23 |
| KR20230087572A (ko) | 2023-06-16 |
| US20230391858A1 (en) | 2023-12-07 |
| JP2023545501A (ja) | 2023-10-30 |
| AU2021361067A1 (en) | 2023-06-01 |
| EP4228696A4 (en) | 2025-03-26 |
| WO2022081997A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007051A2 (pt) | Composições e métodos para tratamento de distúrbios hematológicos | |
| Dekkers et al. | Risky decision making in attention-deficit/hyperactivity disorder: A meta-regression analysis | |
| Ulusoy et al. | Thrombocytopenia in neonates: causes and outcomes | |
| Ward et al. | A global accounting of medically significant scorpions: Epidemiology, major toxins, and comparative resources in harmless counterparts | |
| Penrose | Maternal age in familial mongolism | |
| Dempsey et al. | Mortality in Joubert syndrome | |
| Ruthsatz et al. | Life in plastic, it's not fantastic: sublethal effects of polyethylene microplastics ingestion throughout amphibian metamorphosis | |
| Gandhi et al. | Clinical and laboratory evaluation of patients with febrile thrombocytopenia. | |
| Balistreri et al. | Developmental programming of adult haematopoiesis system | |
| Diaconu et al. | Celiac disease with neurologic manifestations in children | |
| Solorzano et al. | Evolutionary trends of body size and hypsodonty in notoungulates and their probable drivers | |
| Rajkhowa et al. | Temperature and children’s dietary diversity: evidence from India | |
| BR112017002640A2 (pt) | divisão dinâmica computadorizada de interação através de conteúdo múltiplo | |
| MX2020014074A (es) | Iluminacion estructurada de una muestra. | |
| Abbasi et al. | Effectiveness of parent-child interaction therapy on reduction of symptoms in separation anxiety disorder | |
| Kaburaki et al. | Anti-cardiolipin-β2-GPI complex antibodies in idiopathic thrombocytopenic purpura | |
| BR112022022843A2 (pt) | Filtro e aparelho de cozimento | |
| Romstein et al. | Children of imprisoned parents and family ties: What did scientific literatureadvocated during the last 10 years? | |
| Sumangala et al. | A study of clinical and laboratory evaluation and outcome of patients with acute febrile illness with thrombocytopenia | |
| JP2021536635A5 (enExample) | ||
| Irani et al. | Organic neuropsychiatry: a treatable cause of suicidal behaviour | |
| BR112022000226A2 (pt) | Servidor de processamento de informações, método de processamento de informações, programa, e sistema de suporte de provisão de serviços | |
| BR112012018614A2 (pt) | nacela de motor turbojato | |
| Fernandes et al. | Temporal trend and epidemiological profile of accidents involving venomous animals in the State of Rio de Janeiro, Brazil (2012-2021) | |
| Sham | Child homicide in Hong Kong 1989-1998 |